{"id":567925,"date":"2021-10-07T21:30:02","date_gmt":"2021-10-07T21:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=567925"},"modified":"2021-10-07T21:30:02","modified_gmt":"2021-10-07T21:30:02","slug":"riskbased-monitoring-software-market-worth-511-million-by-2025-growing-number-of-clinical-trials-to-propel-market-growth","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/riskbased-monitoring-software-market-worth-511-million-by-2025-growing-number-of-clinical-trials-to-propel-market-growth_567925.html","title":{"rendered":"Risk-based Monitoring Software Market Worth $511 Million by 2025 – Growing Number of Clinical Trials to Propel Market Growth"},"content":{"rendered":"
\n
\"Risk-based<\/a><\/div>\n
\n
Oracle (US), Medidata Solutions (US), and Parexel (US). Other prominent players in the market are Bioclinica (US), Bio-Optronics (US), IBM Corporation (US), DATATRAK (US), Veeva Systems (US), DSG (US), MasterControl (US), ERT (US), Forte Research Systems (US), MedNet Solutions (US), ArisGlobal (US) are key players in Risk-based Monitoring Software Market.<\/div>\n<\/div>\n<\/div>\n
Risk-based Monitoring Software Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size That Will Help Your Business Grow.<\/div>\n

The Report “Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) – Global Forecast to 2025”, <\/strong>published by MarketsandMarkets™, <\/strong>the RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3%.<\/p>\n

Download PDF Brochure: <\/strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=102112429<\/a><\/p>\n

The key factors driving the growth of this market are the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials<\/p>\n

By type, the Enterprise RBM Software segment is expected to account for the largest share of the Risk-based Monitoring Software Market in 2020<\/strong><\/p>\n

Based on type, the market is segmented into Enterprise RBM Software and Site RBM Software. In 2020, the Enterprise RBM Software segment is expected to command the largest share of the market. The large share of this segment can be attributed to the widespread adoption of enterprise RBM software by end-users as it allows all authorized professionals to have access to clinical trial data and metrics placed at a centralized location.<\/p>\n

By component, the software segment is expected to account for the largest share of the RBM software market in 2020<\/strong><\/p>\n

Based on the component, the market is segmented into Software and Services. In 2020, the software segment is expected to command the largest share of the market. The large share of this segment can be attributed to the increasing R&D expenditure in the life science and clinical research industries, increasing number of clinical trials, and rising customer base<\/p>\n

Browse in-depth TOC on<\/em> “<\/strong>Risk-based Monitoring Software Market<\/a>“<\/strong><\/p>\n

114 – Tables<\/strong>
30 – Figures  <\/strong>
137 – Pages<\/strong><\/strong><\/p>\n

By delivery mode, the delivery mode segment is expected to account for the largest share of the RBM software market in 2020<\/strong><\/p>\n

Based on delivery mode, the market is segmented into Web-based (On-demand), Licensed Enterprise (On-premise), and Cloud-based (SaaS). In 2020, the Web-based (On-demand) segment is expected to command the largest share of the market. The large share of this segment can be attributed to the advantages offered by web-based software, such as easy access, improved productivity, time efficiency, and cost-efficiency.<\/p>\n

By end-user, the pharmaceutical and biopharmaceutical companies<\/strong> end-user segment is expected to account for the largest share of the Risk-based Monitoring Software Market in 2020<\/strong><\/p>\n

Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, CROs, medical device companies, and other end users. In 2020, the pharmaceutical and biopharmaceutical companies segment is expected to command the largest share of the RBM software market. The increasing R&D expenditure of pharmaceutical and biopharmaceutical companies is the major factor driving the growth of this end-user segment.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=102112429<\/a>
<\/a><\/p>\n

North America to dominate the market in 2020<\/strong><\/p>\n

North America, Europe, Asia Pacific, and the Rest of the World (RoW) are the regions considered for geographic analysis of the global Risk-based Monitoring Software Market <\/strong>study. North America is expected to account for the largest share of the global market. The large share of North America is attributed to the to the increased adoption of RBM software solutions for clinical trials.<\/p>\n

The prominent players in the global RBM software market include Oracle (US), Medidata Solutions (US), and Parexel (US). Other prominent players in the market are Bioclinica (US), Bio-Optronics (US), IBM Corporation (US), DATATRAK (US), Veeva Systems (US), DSG (US), MasterControl (US), ERT (US), Forte Research Systems (US), MedNet Solutions (US), ArisGlobal (US), Anju Software (US), MaxisIT (US), Techsol Corporation (US), OpenClinica (US), CRF Health (US), and Covance (US).<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/risk-based-monitoring-software-market-102112429.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Oracle (US), Medidata Solutions (US), and Parexel (US). Other prominent players in the market are Bioclinica (US), Bio-Optronics (US), IBM Corporation (US), DATATRAK (US), Veeva Systems (US), DSG (US), MasterControl (US), ERT (US), Forte Research Systems (US), MedNet Solutions (US), … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[421,435,406,403,404],"tags":[],"class_list":["post-567925","post","type-post","status-publish","format-standard","hentry","category-Computers-Software","category-Europe","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/567925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=567925"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/567925\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=567925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=567925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=567925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}